D.A.CH.-Liga Homocystein (German, Austrian, and Swiss Homocysteine Society) consensus paper on the rational clinical use of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases: Guidelines and recommendations;Konsensuspapier der D.A.CH.-Liga homocystein über den rationellen klinischen Umgang mit Homocystein, Folsäure und B-vitaminen bei kardiovaskulären und thrombotischen Erkrankungen - Richtlinien und empfehlungen

Journal fur Kardiologie

Volumn 10, Issue 5, 2003, Pages 190-199

  Stanger, Olaf ^a,g   Herrmann, W ^b   Pietrzik, K ^c   Fowler, B ^d   Geisel, J ^b   Dierkes, J ^e   Weqer, M ^f  

^a Landeskliniken Salzburg   (Austria)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f Universitats Augenklinik   (Austria)

^g Salzburger Landeskliniken   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINOGLUTETHIMIDE; ANTICONVULSIVE AGENT; COLESTIPOL; COLESTYRAMINE; CYANOCOBALAMIN; CYCLOSPORIN A; ESTROGEN; FIBRIC ACID DERIVATIVE; FOLIC ACID; ISONIAZID; LEVODOPA; MESNA; METFORMIN; METHOTREXATE; NICOTINIC ACID; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PENICILLAMINE; PYRIDOXINE; RALOXIFENE; SALAZOSULFAPYRIDINE; TAMOXIFEN; THEOPHYLLINE; TRIMETHOPRIM; VITAMIN B GROUP;

AGING; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CYTOTOXICITY; DIABETES MELLITUS; DIET; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; FOLIC ACID DEFICIENCY; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; MINERAL BALANCE; OXIDATIVE STRESS; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SMOKING; THROMBOSIS; VASCULAR ENDOTHELIUM; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 0038036752     PISSN: 10240098     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Koenig W. Epidemiologie der koronaren Herzkrankheit. Z Kardiol 1998; 87 (Suppl 2): 3-7.
2. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18: 1231-48.
3. Eisenstein EL, Shaw LK, Anstrom KJ, Nelson CL, Hakim Z, Hasselblad V, Mark OB. Assessing the clinical and economic burden of coronary artery disease: 1986-1998.Med Care 2001; 39: 824-35.
4. Klever-Deichert G, Hinzpeter B, Wendland G, Lauterbach K. Kosten-Nutzen-Analyse einer evidenzbasierten Sekundärprävention koronarer Herzkrankheiten durch Statine. Med Klin 2002; 95: 305-13.
5. Liu JL, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart 2002; 88: 597-603.
6. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
7. Erbel R, Siffert W, Mohlenkamp S, Schmermund A. Prävention der KHK durch Risikostratifizierung. Dtsch Med Wochenschr 2003; 128: 330-6.
8. McGill HC Jr, McMahan CA, Herderick EE, Malcom GT, Tracy RE, Strong JP. Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr 2000; 72 (Suppl 5): 1307S-1315S.
9. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 2009; 107: 1562-6.
10. Tsimikas S, Witztum JL. Shifting the diagnosis and treatment of atherosclerosis to children and young adults: a new paradigm for the 21st century. J Am Coll Cardiol 2002; 40: 2122-4.
11. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995; 274: 1049-57.
12. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. J Am Med Assoc 1997; 277: 1775-81.
13. Nagamothu BK, Fendrick AM, Omenn GS. Homocyst(e)ine and coronary heart disease: pharmacoeconomic support for interventions to lower hyperhomocyst(e)ineemia. Pharmacoeconomics 2002; 20: 429-42.
14. Ueland PM, Refsum H, Beresford SA, Volfset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000; 72: 324-32.
15. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002; 325: 1202-8.
16. De Bree A, Verschuren WM, Kromhout D, Kluijtmans LA, Blom HJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 2002; 54: 599-618.
17. De Bree A, Verschuren WM, Kromhout D, Mennen LI, Blom HJ. Homocysteine and coronary heart disease: the importance of a distinction between low and high risk subjects. Int J Epidemiol 2002; 31: 1268-72.
18. Smith SC Jr, Greenland P, Grundy SM. AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. Circulation 2000; 101: 111-6.
19. Wilcken DE, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 1997; 20: 295-300.
20. Clarke R, Collins R. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 1998; 5: 249-55.
21. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
22. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
23. Ubbink JB, van der Merwe A, Delport R, Allen RH, Stabler SP, Riezler R, Vermaak WJ. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 1996; 98:177-84.
24. Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, McCann PP. S-Adenosylmelhionine and methylation. FASEB J 1996; 10: 471-80.
25. 6. Proc Nutr Soc 1994; 53: 625-30.
26. Chasan-Taber L, Selhub J, Rosenberg IH, Malinow MR, Terry P, Tishler PV, Willett W, Hennekens CH, Stampfer MJ. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996; 15: 136-43.
27. Robinson K, Arheart K, Refsum H, Brattstrom L, Boers G, Ueland P, Rubba P, Palma-Reis R, Meleady R, Daly L, Witteman J, Graham I. Low circulating folate and vitamin B6 concentrations: risk factors for stroke. peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 1998; 97: 437-43.
28. Voutilainen S, Rissanen TH, Virtanen J, Lakka TA, Salonen JT. Low dietary folate intake is associated with an excess incidence of acute coronary events: The Kuopio Ischemic Heart Disease Risk Factor Study. Circulation 2001; 103: 2674-80.
29. Kim Yi. Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem 1999; 10: 66-88
30. Stanger O. Physiology of folic acid in health and disease. Curr Drug Metab 2002; 3: 211-23.
31. Shane B, Stokstad EL. Vitamin B12-folate interrelationships. Annu Rev Nutr 1985; 5: 115-41.
32. Ourand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001; 81: 645-72.
33. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
34. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J Am Med Assoc 1993; 270: 2693-8.
35. Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocysteine in plasma and urine. Clin Chem 1985; 31: 624-8.
36. Nurk E, Tell GS, Vollset SE, Nygard O, Refsum H, Ueland PM. Plasma total homocysteine and hospitalizations for cardiovascular disease: the Hordaland Homocysteine Study. Arch Intern Med 2002; 162: 1374-81.
37. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-7.
38. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc 1992; 268: 877-81.
39. Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, Wilson PW, Wolf PA. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999; 131: 352-5.
40. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993; 87: 1107-13.
41. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
42. Becker A, Kostense PJ, Bos G, Heine RJ, Dekker JM, Nijpels G, Beater LM, Stehouwer CD. Hyperhomocysteinaemia is associated with coronary events in type 2 diabetes. J Intern Med 2003; 253: 293-300.
43. Foody JM, Milberg JA, Robinson K, Pearce GL, Jacobsen DW, Sprecher DL. Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol 2000; 20: 493-9.
44. O'Callaghan P, Meleady R, Fitzgerald T, Graham I; European COMAC group. Smoking and plasma homocysteine. Eur Heart J 2002; 23: 1580-6.
45. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LAJ, von den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
46. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritaglou A, Furie KL. Homocysteine, MTHFR 677C→ T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002; 59: 529-36.
47. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies Collaboration Group. MTHFR 677C → T polymorphism and risk of coronary heart disease: a meta-analysis. J Am Med Assoc 2002; 288: 2023-31.
48. Meleady R, Ueland PM, Blom H, Whitehead AS, Refsum H, Daly LE, Vollset SE, Donohue C, Giesendorf B, Graham IM, Ulvik A, Zhang Y, Bjorke Monsen AL. Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project. Am J Clin Nutr 2003; 77: 63-70.
49. Leclerc O, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, Eydoux P, Rosenblatt DS, Rozen R, Gravel RA. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996; 5: 1867-74.
50. 12) increases risk for spina bifida. Mol Genet Metab 1999; 67: 317-23.
51. Schroeder HA. Losses of vitamins and trace minerals resulting from processing and preservation of foods. Am J Clin Nutr 1971; 24: 562-73.
52. De Bree A, van Dusseldorp M, Brouwer IA, van hat Hof KH, Steegers-Theunissen RP. Folate intake in Europe: recommended, actual and desired intake. Eur J Clin Nutr 1997; 51: 643-60.
53. Beitz R, Mensink GB, Fischer B, Thamm M. Vitaminsdietary intake and intake from dietary supplements in Germany. Eur J Clin Nutr 2002; 56: 539-45.
54. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999; 99: 178-82.
55. Herbert V. Vitamin B-12: plant sources, requirements, and assay. Am J Clin Nutr 1998; 48 (Suppl 3): 852-8.
56. 6 in foods. Nutr Rev 1981; 39: 1-8.
57. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. J Am Mad Assoc 1995; 274: 1526-33.
58. Chen P, Poddar R, Tipa EV, Dibello PM, Moravec CD, Robinson K, Green R, Kruger WD, Garrow TA, Jacobsen DW. Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv Enzyme Regul 1999; 39: 93-109.
59. Stanger O, Weger M, Renner W, Konetschny R. Vascular dysfunction in hyperhomocyst(e)inemia. Implications for atherothrombotic disease. Clin Chem Lab Mad 2001; 39: 725-33.
60. Pfeiffer CM, Huff DL, Smith SJ, Miller DT, Gunter EW. Comparison of plasma total homocysteine measurements in 14 laboratories: an international study. Clin Chem 1999; 45: 1261-8.
61. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62.
62. Clarke R, Woodhouse P, Ulvik A, Frost C, Sherliker P, Refsum H, Ueland PM, Khaw KT. Variability and determinants of total homocysteine concentrations in plasma in an elderly population, Clin Chem 1998; 44: 102-7.
63. Garg UC, Zheng ZJ, Folsom AR, Moyer YS, Tsai MY, McGovern P, Eckfeldt JH. Short-term and long-term variability of plasma homocysteine measurement. Clin Chem 1997; 43: 141-5.
64. Clarke R, Shipley M, Lawington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999; 150: 341-53.
65. Clarke R, Lewington S, Donald A, Johnston C, Retsum H, Stratton I, Jacques P, Breteler MM, Holman R. Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. J Cardiovasc Risk 2001; 8: 363-9.
66. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999; 353: 89-92.
67. Doshi SN, Moat SJ, McDowell IF, Lewis MJ, Goodfellow J. Lowering plasma homocysteine with folic acid in cardiovascular disease: what will the trials tell us? Atherosclerosis 2002; 165: 1-3.
68. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, Koudstaal PJ, Grobbee DE. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1999; 159: 38-44.
69. Jacobsen DW. Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998; 44: 1833-43.
70. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992; 12: 279-98.
71. Genest J Jr. Hyperhomocyst(e)inemia-determining factors and treatment. Can J Cardiol 1999; 15: 35B-38B.
72. Graham I. Homocysteine in health and disease. Ann Intern Med 1999; 131: 387-8.
73. Moghadasian MH, McManus BM, Frohlich JJ. Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch Intern Med 1997; 57: 2299-2308.
74. Oakley GP. Eat right and take a multivitamin. N Engl J Med 1998; 338: 1060-1.
75. Omenn GS, Beresford SA, Motulsky AG. Preventing coronary heart disease: B vitamins and homocysteine. Circulation 1998; 97: 421-4.
76. Bailey LB. Dietary reference intakes for folate: the debut of dietary folate equivalents. Nutr Rev 1998; 56: 294-9.
77. Lewis CJ, Crane NT, Wilson DB, Yetley EA. Estimated folate intakes: data updated to reflect food fortification, increased bioavailability, and dietary supplement use. Am J Clin Nutr 1999; 70: 198-207.
78. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Br Med J 1998; 316: 894-8.
79. Herrmann W, Schorr H, Bodis M, Knapp JP, Muller A, Stein G, Geisel J. Role of homocysteine, cystathionine and methylmalonic acid measurement for diagnosis of vitamin deficiency in high-aged subjects. Eur J Clin Invest 2000; 30: 1083-9.
80. Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 1994; 96: 239-46.
81. Butterworth CE, Tamura T. Folic acid safety and toxicity: a brief review. Am J Clin Nutr 1989; 50: 353-8.
82. Bendich A, Cohen M. Vitamin B6 safety issues. Ann N Y Acad Sci 1990; 585: 321-30.
83. Höher M, Hombach V. Klinische und ökonomische Kosten-Nutzen-Relation bei der Behandlung von Patienten mit koronarer Herzerkrankung. Z Kardiol 1998; 87 (Suppl 2): 8-19.
84. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554-72.
85. Ford ES, Byers TE, Giles WH. Serum folate and chronic disease risk: findings from a cohort of United States adults. Int J Epidemiol 1998; 27: 592-8.
86. Loria CM, Ingram DD, Feldman JJ, Wright JD, Madans JH. Serum folate and cardiovascular disease mortality among US men and women. Arch Intern Med 2000; 160: 3258-62.
87. Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, Hennekens C, Stampfer MJ. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. J Am Med Assoc 1998; 279: 359-64.
88. Zeitlin A, Frishman WH, Chang CJ. The association of vitamin B 12 and folate blood levels with mortality and cardiovascular morbidity incidence in the old old: the Bronx aging study. Am J Ther 1997; 4: 275-81.
89. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 1999; 34: 2002-6.
90. Doshi SN, McDowell IF, Moat SJ, Lang D, Newcombe RG, Kredan MB, Lewis MJ, Goodfellow J. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol 2001; 21: 1196-1202.
91. Stanger O, Semmelrock HJ, Wonisch W, Bos U, Pabst E, Wascher TC. Effects of folate treatment and homocysteine lowering on resistance vessel reactivity in atherosclerotic subjects. J Pharmacol Exp Ther 2002; 303: 158-62.
92. Willems FF, Aengevaeren WR, Boers GH, Blom HJ, Verheugt FW. Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 766-72.
93. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet 1998; 351:263.
94. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess DM. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593-600.
95. Schnyder G, Roffi M, Flammer Y, Pin R, Hess DM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. J Am Med Assoc 2002; 288: 973-9.
96. Martin JA, Smith BL, Mathews TJ, Ventura SJ. Births and deaths: preliminary data for 1998. Nat Vital Stat Rep 1999; 47: 1-48.
97. Tice JA, Ross E, Coxson PG, Rosenberg I, Weinstein MC, Hunink MG, Goldman PA, Williams L, Goldman L. Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. J Am Med Assoc 2001; 286: 936-43.
98. Nallamothu BK, Fendrick AM, Rubenfire M, Saint S, Bandekar RR, Omenn GS. Potential clinical and economic effects of homocyst(e)ine lowering. Arch Intern Med 2000; 160: 3406-12.
99. Romano PS, Waitzman NJ, Scheffler RM, Pi RD. Folic acid fortification of grain: an economic analysis. Am J Public Health 1995; 85: 667-76.
100. Tucker KL, Mahnken B, Wilson PW, Jacques P, Selhub J. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. J Am Med Assoc 1996; 276: 1879-85.